Evidence map›Paper›PMID 41897346›Full record

ArticleBiomolecules2026

Licochalcone A as a Potential Anti-

Bing Li, Zexin Tao, Yichen Jing, Yubin Bai, Weiwei Wang, Bintao Zhai, A M Abd El-Aty, Chao Zhang, Jiyu Zhang, Fangdi Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bing LiSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Zexin TaoSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Yichen JingSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.
Yubin BaiLanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China.
Weiwei WangLanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China.
Bintao ZhaiLanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China.
A M Abd El-AtyDepartment of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt.ORCID 0000-0001-6596-7907
Chao ZhangLanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China.
Jiyu ZhangLanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China.
Fangdi HuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis is a zoonotic disease with limited therapeutic options, which are further hampered by significant toxicity and suboptimal efficacy. Effective interventions for chronic infection remain insufficient, and thus, natural product-derived drug screening remains a key focus in anti-

Indexed as

ChalconesToxoplasmaToxoplasmosisAnimalsDrug Evaluation, PreclinicalFemaleMiceMice, Inbred BALB CMolecular Targeted TherapyPersistent InfectionSurface Plasmon ResonanceChalconeslicochalcone AAIlicochalcone ApharmacokineticSPRTgMORN1Toxoplasma gondii

Identifiers

PMID41897346
PMCPMC13024206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.